Agilon Health AGL Earnings Analysis

Revenue Analysis:

Across the recorded periods in 2023, Total Revenue showed slight variations but trended upward from $815.504 million in Q4 to its peak of $1.215 billion in Q3. Similarly, Operating Revenue aligned with these trends. Gross Profit showed variability with significant recovery from -$95.296 million in Q4 to $77.296 million by Q1 2024.

Cost Management:

Cost of Revenue was consistently high, reflecting substantial operational costs, peaking at $1.185 billion in Q3 2023. Operating Expense and Total Expenses both mirrored these high costs, indicating persistent overhead and operating costs throughout the year.

Profitability Analysis:

EBITDA and Operating Income were negative for several quarters, reflecting operational challenges. Notably, EBITDA was as low as -$155.634 million in Q4 2023 but improved in following quarters. Pretax Income showed a recovery from -$162.667 million in Q4 2023 to $14.2 million by Q1 2024. Net Income also recovered from severe losses of -$230.433 million in Q4 2023 to gains of $16.022 million by Q1 2024.

Cash Flow Indicators:

Reconciled Depreciation figures indicate ongoing investment in asset maintenance, whereas Interest Expense displayed general consistency—both critical for evaluating operational sustainability and financing costs.

Taxation:

The Tax Rate remained steady at 21%. The Tax Provision varied, highlighting a deferred tax asset of $1.21 million in Q3, improving the company’s tax position, before transitioning to a tax benefit by Q1 2024.

Shareholder Metrics:

Diluted EPS and Basic EPS saw an improvement from -0.08 in Q4 2023 to 0.04 by Q1 2024 indicating a per-share earnings recovery. Diluted Average Shares and Basic Average Shares showed an increase, suggesting a dilution of shareholder value. However, Net Income Available to Common Stockholders rebounded, providing a more favorable outlook for investors.

Conclusion:

Despite a challenging fiscal year in 2023 with significant losses, AGL demonstrated significant improvement in profitability by early 2024. Recovery in net income and stabilization in gross profit margins are positive indicators. However, high operational and interest expenses remain a concern. AGL would benefit from strategic cost management and efficiency enhancements to sustain its recovery trajectory and improve shareholder returns.